2014-12-01から1ヶ月間の記事一覧
First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial (Lancet Haematology 2014;1:e104-e1…
Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma (Br J Haematol 2015;168:55-62) プロテアソーム阻害剤であるボルテゾミブ(BOR)は，細胞の化学療法に対する感受性を増大させ…
Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma (Br J Harmatol 2015;168:46-54) この単施設，オープンラベル第I/II相用量増量試験では，再発・難…
Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas (JCO 2014;32:3490-…
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma (NEJM, DOI: 10.1056/NEJMoa1411321) 背景 レナリドミド＋デキサメタゾンは骨髄腫再発時において基準となる治療である．プロテアソーム阻害薬であるcarfilzomibをレナリドミド…
Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study (JCO 2014;32:3736-3743) 目的 リツキシマブ併用化学療法を受けたHBs抗原陰性，抗HBc抗…
